CStone Pharmaceuticals is a clinical stage biopharmaceutical company devoted to the development of innovative drugs. With a broad pipeline, the company engages in the development of cancer therapeutics with a special focus on immuno-oncology based combination therapies. All members of the management team are seasoned executives from top multinational pharmaceutical companies. CStone has successfully built up its core competency in clinical development and translational medicine. The company is backed by prestigious VC/PE funds via two financing rounds to date, raising $150 million in a Series A round in July 2016, followed by $260 million in a Series B round in May 2018. With an experienced team, a rich pipeline, a robust R&D model, and substantial funding, CStone is well positioned as the partner of choice for multinational pharmaceutical / biotech companies to develop drugs in China and the Asia-Pacific region.For more information about CStone Pharmaceuticals, please visit: www.cstonepharma.com

IMMUNOTHERAPY
Immunotherapies activate or enhance the body’s immune system to overcome “immune-evasion” by identifying and attacking cancer cells; such therapies produce durable therapeutic benefit for a broad spectrum of cancer types with very mild toxicity, but they are only effective for a small subset of patients.

ABOUT CS1001
CS1001 (formerly codenamed WBP3155), independently developed and wholly owned by CStone Pharmaceuticals, is the first fully human, full-length innovative anti-PD-L1 drug candidate in China. Authorized by the U.S. based Ligand Corporation, CS1001 is also the first monoclonal antibody developed by the world leading OMT transgenic animal platform, which can generate fully human antibodies in one step.